The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Bright Minds Biosciences Inc (NASDAQ: DRUG) closed at $41.80 in the last session, down -8.57% from day before closing price of $45.72. In other words, the price has decreased by -$8.57 from its previous closing price. On the day, 79505.0 shares were traded. DRUG stock price reached its highest trading level at $46.7151 during the session, while it also had its lowest trading level at $40.3047.
Ratios:
We take a closer look at DRUG’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 126.15 and its Current Ratio is at 126.15. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on January 23, 2025, initiated with a Overweight rating and assigned the stock a target price of $93.
On January 10, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $85.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 04 ’24 when Cormorant Asset Management, LP bought 184,331 shares for $21.70 per share. The transaction valued at 3,999,983 led to the insider holds 1,059,331 shares of the business.
Cormorant Asset Management, LP bought 372,591 shares of DRUG for $2,061,574 on Oct 15 ’24. The 10% Owner now owns 825,000 shares after completing the transaction at $5.53 per share. On Oct 16 ’24, another insider, Cormorant Asset Management, LP, who serves as the 10% Owner of the company, bought 50,000 shares for $23.46 each. As a result, the insider paid 1,172,813 and bolstered with 875,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DRUG now has a Market Capitalization of 300283680 and an Enterprise Value of 236724816.
Stock Price History:
The Beta on a monthly basis for DRUG is -6.69, which has changed by 21.352942 over the last 52 weeks, in comparison to a change of 0.22894537 over the same period for the S&P500. Over the past 52 weeks, DRUG has reached a high of $79.02, while it has fallen to a 52-week low of $0.93. The 50-Day Moving Average of the stock is 8.93%, while the 200-Day Moving Average is calculated to be 138.49%.
Shares Statistics:
According to the various share statistics, DRUG traded on average about 114.35K shares per day over the past 3-months and 67440 shares per day over the past 10 days. A total of 6.99M shares are outstanding, with a floating share count of 5.16M. Insiders hold about 26.81% of the company’s shares, while institutions hold 58.92% stake in the company. Shares short for DRUG as of 1738281600 were 137699 with a Short Ratio of 1.20, compared to 1735603200 on 176685. Therefore, it implies a Short% of Shares Outstanding of 137699 and a Short% of Float of 2.87.
